Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2015 / Aug / Standardizing Stem Cell Selection
Retina Retina Research & Innovations

Standardizing Stem Cell Selection

Stem cell therapies may be the future of treating retinal disease, but how do you choose the best source?

By Roisin McGuigan 8/11/2015 1 min read

Share

Stem cell therapies hold tremendous potential for treating ophthalmic disease, but as the field is still relatively young, many questions remain unanswered. One research team, led by staff from St. Jude Children’s Research Hospital, set out to discover more about the biology of stem cells by posing a question: how do you identify the best stem cell source for transplantation into the retina?

The team examined three stem cell types: embryonic stem cells (ESCs), fibroblast-derived induced pluripotent stem cells (f-iPSCs), and iPSCs derived from murine rod photoreceptors (r-iPSCs), all of which are able to produce retinal pigment epithelium (RPE) in culture. The different types of cells produced were then compared using the STEM-RET protocol, which quantifies retinogenesis using measurements of molecular, cellular and morphological criteria. The researchers found that r-iPSCs are more efficient at producing differentiated RPE, whereas f-iPSCs show reduced numbers of inner nuclear layer and ganglion cell layer cells. “There has long been a debate in the field about how to standardize the quantification of stem cell differentiation,” says Michael Dyer, lead author of the study (1), adding, “Our STEM-RET method enables that standardization, which means that laboratories can accurately compare their results with one another and different stem cell lines can be compared. We believe the method could be adopted widely.” But why might r-iPSCs make superior RPE cells? One factor might be epigenetic memory – the photoreceptor-derived cells retain distinct epigenetic switches after being reprogrammed, which affects how well they can produce different cell types and could explain why rod-derived stem cells are better than other types at creating differentiated retinal cells. Dyer hopes that using this information to create epigenetic “fingerprints” could allow for better selection of cells for therapeutic purposes.

References

  1. D Hiler, et al., “Quantification of retinogenesis in 3D cultures reveals epigenetic memory and higher efficiency in IPSCs derived from rod photoreceptors”, Cell Stem Cell, 17, 101–115 (2015). PMID: 26140606.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: